Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q0WX57

UPID:
U17LO_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 17; Ubiquitin thioesterase 17; Ubiquitin-specific-processing protease 17

ALTERNATIVE UPACC:
Q0WX57; A8MRA9; Q0WX56; Q3BEM1

BACKGROUND:
The protein Ubiquitin carboxyl-terminal hydrolase 17-like protein 24, with alternative names such as Deubiquitinating enzyme 17, Ubiquitin thioesterase 17, and Ubiquitin-specific-processing protease 17, is integral to cellular homeostasis. By removing ubiquitin from proteins, it influences cell proliferation, cell cycle, apoptosis, migration, and response to viruses, showcasing its versatility and importance in cellular functioning.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin carboxyl-terminal hydrolase 17-like protein 24 holds promise for identifying novel therapeutic approaches. Its critical role in various cellular processes makes it an attractive target for developing drugs that could modulate its deubiquitinating activity for treating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.